Abstract
In the advanced/metastatic Neuroendocrine tumors (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity, including therapy-related myeloid neoplasms (t-MN). Here, we assessed the effect of PRRT on the development of t-MN and clonal hematopoiesis (CH) known to be a risk factor for t-MN development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have